{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T08:37:47Z","timestamp":1648802267292},"reference-count":38,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2014,4,1]],"date-time":"2014-04-01T00:00:00Z","timestamp":1396310400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Actas Urol\u00f3gicas Espa\u00f1olas"],"published-print":{"date-parts":[[2014,4]]},"DOI":"10.1016\/j.acuro.2013.07.008","type":"journal-article","created":{"date-parts":[[2013,10,8]],"date-time":"2013-10-08T12:15:52Z","timestamp":1381234552000},"page":"156-163","source":"Crossref","is-referenced-by-count":1,"title":["Beneficio terap\u00e9utico tras cambiar tolterodina por otros nuevos antimuscar\u00ednicos"],"prefix":"10.1016","volume":"38","author":[{"given":"F.","family":"S\u00e1nchez-Ballester","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Miranda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I.","family":"Lizarraga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Rejas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Arumi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.acuro.2013.07.008_bib0005","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/S0210-4806(05)73192-2","article-title":"Terminology for lower urinary tract function","volume":"29","author":"Martinez","year":"2005","journal-title":"Actas Urol Esp"},{"key":"10.1016\/j.acuro.2013.07.008_bib0010","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/S2173-5786(11)70022-1","article-title":"Assessment of reasons for overactive bladder treatment change","volume":"35","author":"Castro","year":"2011","journal-title":"Actas Urol Esp"},{"key":"10.1016\/j.acuro.2013.07.008_bib0015","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1002\/nau.10052","article-title":"The standardisation of terminology of lower urinary tract function: Report from the Standardisation Sub-committee of the International Continence Society","volume":"21","author":"Abrams","year":"2002","journal-title":"Neurourol Urodyn"},{"key":"10.1016\/j.acuro.2013.07.008_bib0020","first-page":"159","article-title":"Prevalence of urinary incontinence and hyperactive bladder in the Spanish population: Results of the EPICC study","volume":"33","author":"Martinez","year":"2009","journal-title":"Actas Urol Esp"},{"issue":"11 Suppl","key":"10.1016\/j.acuro.2013.07.008_bib0025","first-page":"S580","article-title":"Overactive bladder significantly affects quality of life","volume":"6","author":"Abrams","year":"2000","journal-title":"Am J Manag Care"},{"key":"10.1016\/j.acuro.2013.07.008_bib0030","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1111\/j.1524-4733.2004.74008.x","article-title":"The impact of urinary urgency and frequency on health-related quality of life in overactive bladder: Results from a national community survey","volume":"7","author":"Coyne","year":"2004","journal-title":"Value Health"},{"issue":"Pt 2","key":"10.1016\/j.acuro.2013.07.008_bib0035","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1348\/135910707X187786","article-title":"It's just the worry about not being able to control it! A qualitative study of living with overactive bladder","volume":"13","author":"Nicolson","year":"2008","journal-title":"Br J Health Psychol"},{"key":"10.1016\/j.acuro.2013.07.008_bib0040","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1056\/NEJMra032662","article-title":"Management of overactive bladder","volume":"350","author":"Ouslander","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.acuro.2013.07.008_bib0045","doi-asserted-by":"crossref","first-page":"869","DOI":"10.2147\/TCRM.S6483","article-title":"Fesoterodine for the treatment of urinary incontinence and overactive bladder","volume":"5","author":"Ellsworth","year":"2009","journal-title":"Ther Clin Risk Manag"},{"key":"10.1016\/j.acuro.2013.07.008_bib0050","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1016\/j.eururo.2004.11.004","article-title":"Long-term open-label solifenacin treatment associated with persistence with therapy in patients with overactive bladder syndrome","volume":"47","author":"Haab","year":"2005","journal-title":"Eur Urol"},{"key":"10.1016\/j.acuro.2013.07.008_bib0055","doi-asserted-by":"crossref","first-page":"291","DOI":"10.18553\/jmcp.2008.14.3.291","article-title":"Persistence, adherence, and switch rates among extended-release and immediate-release overactive bladder medications in a regional managed care plan","volume":"14","author":"D'Souza","year":"2008","journal-title":"J Manag Care Pharm"},{"key":"10.1016\/j.acuro.2013.07.008_bib0060","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/1471-2490-12-19","article-title":"Dose and aging effect on patients reported treatment benefit switching from the first overactive bladder therapy with tolterodine ER to fesoterodine: Post-hoc analysis from an observational and retrospective study","volume":"12","author":"Castro-Diaz","year":"2012","journal-title":"BMC Urol"},{"key":"10.1016\/j.acuro.2013.07.008_bib0065","doi-asserted-by":"crossref","first-page":"305","DOI":"10.2165\/00044011-200929050-00003","article-title":"Diary and patient-reported outcomes in patients with severe overactive bladder switching from tolterodine extended release 4mg\/day to solifenacin treatment: An open-label, flexible-dosing, multicentre study","volume":"29","author":"Swift","year":"2009","journal-title":"Clin Drug Investig"},{"key":"10.1016\/j.acuro.2013.07.008_bib0070","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1111\/j.1742-1241.2008.01893.x","article-title":"Darifenacin treatment for overactive bladder in patients who expressed dissatisfaction with prior extended-release antimuscarinic therapy","volume":"62","author":"Zinner","year":"2008","journal-title":"Int J Clin Pract"},{"key":"10.1016\/j.acuro.2013.07.008_bib0075","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.1016\/j.clinthera.2008.10.011","article-title":"Efficacy of solifenacin in patients previously treated with tolterodine extended release 4mg: Results of a 12-week, multicenter, open-label, flexible-dose study","volume":"30","author":"Chancellor","year":"2008","journal-title":"Clin Ther"},{"key":"10.1016\/j.acuro.2013.07.008_bib0080","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1016\/j.eururo.2007.07.009","article-title":"Clinical efficacy, safety, and tolerability of once-daily fesoterodine in subjects with overactive bladder","volume":"52","author":"Chapple","year":"2007","journal-title":"Eur Urol"},{"key":"10.1016\/j.acuro.2013.07.008_bib0085","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1111\/j.1464-410X.2008.07907.x","article-title":"Comparison of fesoterodine and tolterodine in patients with overactive bladder","volume":"102","author":"Chapple","year":"2008","journal-title":"BJU Int"},{"key":"10.1016\/j.acuro.2013.07.008_bib0090","doi-asserted-by":"crossref","first-page":"2488","DOI":"10.1016\/j.juro.2007.08.033","article-title":"Efficacy, safety and tolerability of fesoterodine for overactive bladder syndrome","volume":"178","author":"Nitti","year":"2007","journal-title":"J Urol"},{"issue":"5 Pt 1","key":"10.1016\/j.acuro.2013.07.008_bib0095","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1097\/01.ju.0000140729.07840.16","article-title":"Randomized, double-blind placebo controlled trial of the once daily antimuscarinic agent solifenacin succinate in patients with overactive bladder","volume":"172","author":"Cardozo","year":"2004","journal-title":"J Urol"},{"key":"10.1016\/j.acuro.2013.07.008_bib0100","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1111\/j.1464-410X.2008.07939.x","article-title":"Solifenacin in the treatment of urgency and other symptoms of overactive bladder: results from a randomized, double-blind, placebo-controlled, rising-dose trial","volume":"102","author":"Cardozo","year":"2008","journal-title":"BJU Int"},{"key":"10.1016\/j.acuro.2013.07.008_bib0105","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1111\/j.1742-1241.2009.02035.x","article-title":"Effects of flexible-dose fesoterodine on overactive bladder symptoms and treatment satisfaction: An open-label study","volume":"63","author":"Wyndaele","year":"2009","journal-title":"Int J Clin Pract"},{"key":"10.1016\/j.acuro.2013.07.008_bib0110","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1097\/00005650-198601000-00007","article-title":"Concurrent and predictive validity of a self-reported measure of medication adherence","volume":"24","author":"Morisky","year":"1986","journal-title":"Med Care"},{"key":"10.1016\/j.acuro.2013.07.008_bib0115","series-title":"Clinical global impressions: In ECDEU assessment manual for psychopharmacology. Revised DHEW Pub. (ADM)","first-page":"218","author":"Guy","year":"1976"},{"key":"10.1016\/j.acuro.2013.07.008_bib0120","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1016\/j.urology.2008.05.033","article-title":"Validation of treatment benefit scale for assessing subjective outcomes in treatment of overactive bladder","volume":"72","author":"Colman","year":"2008","journal-title":"Urology"},{"key":"10.1016\/j.acuro.2013.07.008_bib0125","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1093\/biomet\/70.1.41","article-title":"The central role of the propensity score in observational studies for causal affects","volume":"70","author":"Rosenbaum","year":"1983","journal-title":"Biometrika"},{"key":"10.1016\/j.acuro.2013.07.008_bib0130","first-page":"358","article-title":"Use of the propensity score methodology in health care research","volume":"208","author":"Exposito","year":"2008","journal-title":"Rev Clin Esp"},{"key":"10.1016\/j.acuro.2013.07.008_bib0135","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/S1138-3593(03)74245-2","article-title":"El control de la confusi\u00f3n en estudios observacionales: el \u00edndice de propensi\u00f3n","volume":"29","author":"Abraira","year":"2003","journal-title":"Semergen"},{"key":"10.1016\/j.acuro.2013.07.008_bib0140","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1111\/j.1464-410X.2010.09640.x","article-title":"Superior efficacy of fesoterodine over tolterodine extended release with rapid onset: A prospective, head-to-head, placebo-controlled trial","volume":"107","author":"Kaplan","year":"2011","journal-title":"BJU Int"},{"key":"10.1016\/j.acuro.2013.07.008_bib0145","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1111\/j.1464-410X.2009.09086.x","article-title":"Comparison of fesoterodine and tolterodine extended release for the treatment of overactive bladder: A head-to-head placebo-controlled trial","volume":"105","author":"Herschorn","year":"2010","journal-title":"BJU Int"},{"key":"10.1016\/j.acuro.2013.07.008_bib0150","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1111\/j.1464-410X.2004.04606.x","article-title":"Randomized, double-blind placebo- and tolterodine-controlled trial of the once-daily antimuscarinic agent solifenacin in patients with symptomatic overactive bladder","volume":"93","author":"Chapple","year":"2004","journal-title":"BJU Int"},{"key":"10.1016\/j.acuro.2013.07.008_bib0155","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/j.eururo.2005.05.015","article-title":"A comparison of the efficacy and tolerability of solifenacin succinate and extended release tolterodine at treating overactive bladder syndrome: Results of the STAR trial","volume":"48","author":"Chapple","year":"2005","journal-title":"Eur Urol"},{"key":"10.1016\/j.acuro.2013.07.008_bib0160","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.acuroe.2012.05.016","article-title":"New perspectives of treatment with fesoterodine fumarate in patients with overactive bladder","volume":"37","author":"Garcia-Baquero","year":"2013","journal-title":"Actas Urol Esp"},{"key":"10.1016\/j.acuro.2013.07.008_bib0165","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1111\/j.1464-410X.2009.08545.x","article-title":"Listening to the patient: A flexible approach to the use of antimuscarinic agents in overactive bladder syndrome","volume":"104","author":"Chapple","year":"2009","journal-title":"BJU Int"},{"key":"10.1016\/j.acuro.2013.07.008_bib0170","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1007\/s11934-003-0025-z","article-title":"Overactive bladder: Improving the efficacy of anticholinergics by dose escalation","volume":"4","author":"MacDiarmid","year":"2003","journal-title":"Curr Urol Rep"},{"key":"10.1016\/j.acuro.2013.07.008_bib0175","doi-asserted-by":"crossref","first-page":"943","DOI":"10.2147\/IJGM.S24236","article-title":"Overactive bladder, differential diagnosis, and clinical utility of fesoterodine","volume":"5","author":"Wyndaele","year":"2012","journal-title":"Int J Gen Med"},{"key":"10.1016\/j.acuro.2013.07.008_bib0180","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/j.urology.2007.12.017","article-title":"Fesoterodine dose response in subjects with overactive bladder syndrome","volume":"71","author":"Khullar","year":"2008","journal-title":"Urology"},{"key":"10.1016\/j.acuro.2013.07.008_bib0185","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1111\/j.1464-410X.2012.11654.x","article-title":"Severity of overactive bladder symptoms and response to dose escalation in a randomized, double-blind trial of solifenacin (SUNRISE)","volume":"111","author":"Cardozo","year":"2013","journal-title":"BJU Int"},{"key":"10.1016\/j.acuro.2013.07.008_bib0190","doi-asserted-by":"crossref","first-page":"281","DOI":"10.2165\/00003088-200948050-00001","article-title":"Clinical pharmacokinetics and pharmacodynamics of solifenacin","volume":"48","author":"Doroshyenko","year":"2009","journal-title":"Clin Pharmacokinet"}],"container-title":["Actas Urol\u00f3gicas Espa\u00f1olas"],"original-title":[],"language":"es","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S021048061300301X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S021048061300301X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,3,8]],"date-time":"2022-03-08T08:39:57Z","timestamp":1646728797000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S021048061300301X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,4]]},"references-count":38,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2014,4]]}},"alternative-id":["S021048061300301X"],"URL":"https:\/\/doi.org\/10.1016\/j.acuro.2013.07.008","relation":{},"ISSN":["0210-4806"],"issn-type":[{"value":"0210-4806","type":"print"}],"subject":[],"published":{"date-parts":[[2014,4]]}}}